Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent after receiving a full explanation of the trial and choosing to take part voluntarily
• Adults aged 19 years or older
• People who have been diagnosed with advanced (stage IV) non-small cell lung cancer, confirmed by laboratory testing of tissue or cell samples; if the cancer has come back, it must have spread to areas outside the chest
• People whose cancer is planned to be treated with pembrolizumab (an immunotherapy drug) as the first treatment, and whose tumour tests show a PD-L1 score of 50% or higher with no EGFR or ALK gene mutations present
• People with a life expectancy of at least 3 months
• People who are reasonably active and able to care for themselves, based on a standard medical scoring system (ECOG score of 0, 1, or 2)
• People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines
• People whose blood and organ function test results meet certain minimum levels, including healthy enough levels of red blood cells, white blood cells, and platelets, as well as adequate kidney and liver function (confirm with trial site for specific values)

Who may not be able to join:

• People who have active cancer that has spread to the brain and is causing noticeable neurological symptoms
• People who have been diagnosed with another separate cancer in the past 5 years that could affect the lung cancer, with some exceptions for certain previously treated and cured cancers (confirm with trial site)
• People who have been treated with certain immunotherapy drugs (immune checkpoint inhibitors or anti-CTLA-4 treatments) in the past 6 weeks, or with immune-suppressing medications in the past 2 weeks, with some exceptions for low-dose steroids
• People currently taking thiazide or loop diuretics (a type of fluid or blood pressure medication)
• People with low potassium levels in the blood (below 3.0 mEq/L)
• People with active lung inflammation (interstitial lung disease) that requires steroid treatment taken by mouth or through a drip
• People with an autoimmune disease that currently requires ongoing medical treatment
• People with diabetes that is not well controlled despite medication, based on specific blood sugar and HbA1c measurements
• People with high blood pressure that remains uncontrolled despite taking blood pressure medication
• People with serious uncontrolled heart conditions, such as severe heart failure, unstable chest pain, or certain irregular heart rhythms
• People with certain rare inherited conditions affecting how the body processes sugars, such as galactose intolerance or glucose-galactose malabsorption
• People with a known active or uncontrolled infection with HIV, tuberculosis, hepatitis B, or hepatitis C
• People who are pregnant or currently breastfeeding
• People who do not agree to use effective contraception during the trial and for at least 5 months after the last dose of the study treatment
• People who have taken herbal medicines in the 4 weeks before starting the study treatment, if the trial doctor considers this could affect the trial or the person's safety
• People who have taken part in another clinical trial and received an experimental drug within 30 days before starting this study treatment
• People who have had a severe allergic skin reaction to the study treatment or its ingredients (such as rash, hives, or eczema)
• People who the trial doctor considers unsuitable for any other reason, such as serious infection or organ failure

Important: Always verify eligibility with the trial site directly before applying.